Silverarc Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Silverarc Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-457,414	Closed	-$5.3M	–	99
2025 Q3	$5.3M	Sell	457,414 -155,979	-25%	-$1.63M	0.71%	37
2025 Q2	$6.51M	Hold	613,393	–	–	1.2%	23
2025 Q1	$6.93M	Buy	613,393 +100,024	+19%	+$1.08M	1.42%	24
2024 Q4	$5.39M	Hold	513,369	–	–	1.18%	30
2024 Q3	$5.36M	Buy	513,369 +13,369	+3%	+$138K	1.2%	29
2024 Q2	$5.11M	Hold	500,000	–	–	1.21%	27
2024 Q1	$5.2M	Buy	+500,000	New	+$5.18M	1.44%	25

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Silverarc Capital Management's BBOT Position: Q4 2025 in Review

Silverarc Capital Management sold out of BridgeBio Oncology (BBOT) in Q4 2025, closing a stake of 457,414 shares — an estimated $5.3M sold.

Silverarc Capital Management first reported a position in BBOT in Q1 2024 and held it in 7 quarters. The position peaked at $6.93M in Q1 2025. 53 funds tracked by Wall St. Rank hold BBOT as of Q4 2025.

Silverarc Capital Management reported no remaining BridgeBio Oncology position as of Q4 2025 after selling out during the quarter.
Silverarc Capital Management sold 457,414 BridgeBio Oncology shares in Q4 2025, an estimated $5.3M.
Silverarc Capital Management first reported a position in BridgeBio Oncology in Q1 2024 and held it in 7 quarters.
Silverarc Capital Management's BridgeBio Oncology position peaked at $6.93M in Q1 2025.
53 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.